Radioligand therapy continues to gain momentum as a transformative approach in oncology. A recent analysis of PubMed publications highlights a steady and significant increase in peer-reviewed papers on clinical therapeutic radionuclides between 2000 and 2024.
This graph shows the growing number of publications categorized by radionuclide. Among the 13 radionuclides represented, 177Lu dominates the landscape (red portion of the bar), which is expected given that the two main therapies, Lutathera and Pluvicto, are based on 177Lu.Hits of PubMed Primary Articles on All Clinical Therapeutic Radionuclides from 2000 to 2024
The data, adapted from Radiotheranostic landscape: A review of clinical and preclinical development (Tran et al., 2025), underscores the rapid progress being made in the field and signals an exciting future for radiotheranostics.
Interested in how these trends may impact your business? Connect with Bracken to learn how our team can guide your next steps in radiopharmaceutical development.
Reference: Tran HH, Yamaguchi A, Manning HC. Radiotheranostic landscape: A review of clinical and preclinical development. Eur J Nucl Med Mol Imaging. 2025.